Please ensure Javascript is enabled for purposes of website accessibility

Better Marijuana Stock: Aurora Cannabis vs. Cresco Labs

By Keith Speights - Jun 21, 2020 at 2:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's Canada against the U.S. in this cannabis contest.

This year has already been a study in contrasts for Aurora Cannabis (ACB 8.55%) and Cresco Labs (CRLBF 1.30%). By the end of March, both cannabis companies had seen their valuations more than halved. But since April, shares of both Aurora and Cresco have soared.

Cresco Labs has been the bigger winner in recent months. But which of these marijuana stocks is the better pick for long-term investors?

Two tiny shopping carts with a cannabis plant on top of them

Image source: Getty Images.

The case for Aurora Cannabis

Are happy days here again for Aurora Cannabis? Some might think so. The Canadian cannabis producer delivered surprisingly good fiscal 2020 third-quarter results. Revenue jumped 18% from the previous quarter thanks in large part to strong demand for Aurora's Daily Special value brand.

Aurora also seems to be making progress toward profitability. The company has cut back drastically on its spending. It hopes to generate positive adjusted EBITDA in the quarter ending Sept. 30, 2020. 

After a temporary suspension in Germany, Aurora is now back in full swing in the key European medical cannabis market. At long last, Aurora is also now poised to enter the U.S. CBD market. In May, the company announced that it is acquiring Reliva, which ranks as one of the top-selling hemp-derived CBD brands in the U.S. Reliva's products are carried in more than 20,000 retail stores. 

There are reasons for optimism in Aurora's home market of Canada as well. The retail picture should improve as the Canadian economy emerges from the shadow of the COVID-19 pandemic. New retail cannabis stores are set to open in the country's most heavily populated province, Ontario.

Canada's "Cannabis 2.0" cannabis derivatives market should also continue to gain momentum. Aurora is already enjoying solid sales growth from its vapes and edibles and could see even stronger growth over the next year.

Despite its challenges over the last year, Aurora remains one of the market leaders in the Canadian cannabis industry. The company still claims an impressive production capacity. And its cost structure for cultivating cannabis is among the lowest in the industry. 

The case for Cresco Labs

Cresco Labs doesn't just hope to generate positive adjusted EBITDA. The company has already achieved that goal for four quarters in a row. And while Cresco isn't yet profitable, it's not too hard to see how the cannabis operator could deliver a positive bottom line in the near future.

One key for Cresco to achieve profitability is to keep up its remarkable growth. In the first quarter of 2020, the company generated 60% quarter-over-quarter revenue growth. Granted, much of that increase stemmed from Cresco's acquisition of Origin House earlier this year. However, the company still managed to grow sales organically by 26% over the previous quarter.

This growth is coming in large part in two markets -- Illinois (where Cresco is headquartered) and Pennsylvania. Illinois launched its recreational marijuana market this year and has seen robust sales so far. Pennsylvania's medical cannabis market opened in 2018 and continues to pick up momentum.

Cresco's acquisition of Origin House should pave the way for growth in California, the largest legal cannabis market in the U.S. Origin House ranks as one of the largest cannabis distributors in the state and also markets its own family of cannabis brands.

Ohio seems likely to present another significant growth opportunity for Cresco. The company recently won a provisional license in the state that allows it to market its cannabis derivative products, including edibles and oils.

There are plenty of other markets in which Cresco can grow as well. The cannabis operator currently operates in nine states, but 33 states so far have legalized cannabis in some form. And with the prospects that New Jersey citizens could vote to legalize recreational marijuana in November, another major market could soon open up for Cresco.

Better marijuana stock

One of these stocks is growing faster than the other. It's already generating positive adjusted EBITDA. It already operates in the largest legal cannabis market in the world. And its market cap is much smaller than the other contender's market cap. In my opinion, Cresco Labs is the clear winner versus Aurora Cannabis. The choice is an easy one.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Cresco Labs Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.63 (8.55%) $0.13
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
CRLBF
$3.56 (1.30%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.